Lead Acid Battery Market 2022 Outlook, Current and Future Industry Landscape Analysis 2031

The global sales of lead acid battery are set to be valued at over US$ 54.3 Bn in 2021, with a stable long-term projection, according to latest insights by Future Market Insights (FMI). The report has forecast the market to expand at over 5.2% CAGR between 2021 and 2031.

According to the market analysis by Future Market Insights, expansion of automotive production facilities to cover rural and other remote areas has led to the increasing demand for lead acid battery. Rapid technological advancements in production technologies are also projected to complement market growth over the coming years.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-54

Demand for lead acid battery is increasing with the rise in the volume of vehicle fleet in recent years. This can be attributed to an increase in aftermarket sales in regular interims for battery replacement.

The growing requirement has led to mass production and has increased importance of process automation in the lead acid battery market. The market is shifting towards industry 4.0 s, leading to the universal adoption of new production technologies.

There also is an increasing demand from other industries for deployment of lead acid battery. Increasing number of players focusing on research and development related to lead acid battery is anticipated to have a significant contribution towards market growth in the years to come.

Key Takeaways from Lead Acid Battery Market Study

  • Flooded battery is projected to hold over 49% of the global market share in 2021 in terms of product type, supported by superior configurations.
  • Transportation is projected to hold over 56% of the overall market share as leading segment in terms of application by 2031-end, supported by increasing investments in electric vehicles production.
  • China will remain a chief market, backed by rising demand from the automotive industry. It is expected to account for over 57.3% of demand registered in East Asia in 2021.
  • The markets India is set to surge at around 6% CAGR over the next ten years.
  • Germany is emerging as a key market in Europe, accounting for over US$ 2,509.4 Mn in 2021, driven by expansion of the automotive industry.

“The lead acid battery market is growing at a strong pace, driven largely by increasing demand for energy efficient solutions across automotive sector. The increasing demand for electric vehicles will create extensive opportunities for manufacturers. Key industry participants have been focusing product diversification to offer energy efficient solutions and gain a competitive advantage,” says a Future Market Insights analyst

Ask An Analyst @ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-54

Competitive Landscape

The lead acid battery market is highly competitive at regional as well as global levels, and highly consolidated in nature. These players are likely to invest in new technology developments and expansion of their networks in order to maintain their market shares.

Some of the key players in this industry include but are not limited to Furukawa Electric Co., Ltd., Narada Power Source Co. Ltd., Clarios, Leoch International Technology Ltd., Enersys, Exide Industries Ltd., GS Yuasa Corporation, East Penn Manufacturing Co., Chaowei Power Holdings Limited., and others.

Find More Valuable Insights

The research report analyzes demand for Lead Acid Battery. The global Lead Acid Battery market has been analyzed with the COVID-19 impact, various macroeconomic factors, market trends and market background. As per Future Market Insights, the market has been analyzed on the basis of product type, power source, and region. The report provides qualitative and quantitative information on various players in this market. This report also tracks the market by both, supply side and demand factors.

Key Questions Answered in the Report

  • What is the current valuation of lead acid battery market?
  • At what rate will the Japan lead acid battery market grow?

Buy Complete Report @ https://www.futuremarketinsights.com/checkout/54

Contact Us:                                                            

Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Whole Genome Amplification Market 2021 Outlook, Current and Future Industry Landscape Analysis 2031

The global whole genome amplification market is estimated at around US$ 5.08 Bn by the end of 2031, as indicated by a recent report released by Future Market Insights. The global market for whole genome amplification will possibly expand at a CAGR of 7.9% during the forecast period, 2021-2031

A US-based team of researchers has recently developed a microfluidic device for isolating a genomic DNA, which is to be purified later. This DNA is sourced from individual cells and the device physically catches single cells using a micropillar array.

It also captures chromosomal DNA of these single cells post-extraction, which is later immobilized in the micropillar array so as to enable the process of isothermal amplification. The entire methodology is referred to as ‘on-chip cell capture and DNA extraction’.

As conventional single cell WGA is often prone to amplification biases, which may hold a significant influence on the accuracy of the data of single cell sequencing.

This drawback is foreseen to be overcome with the introduction of single cell on-chip WGA, resulting in reduced biases regarding amplification, offering an improved coverage of the genome. The team has used individual cancer cell genomes (human), sourced from the HeLa Cell Line.

WGA has been a crucial procedure that helps in DNA analysis from limited quantities of genomic DNA. The ease provided by various WGA kits available for the entire process has been driving the market over the years.

Increasing research activities will remain the key factor pushing the growth of whole genome amplification market over the next decade. Adoption of this process is expected to witness robust growth, predominantly among research institutes, hospitals, diagnostic centers, and forensic labs, as it offers an improved and advanced means of genome amplification and sequencing.

To increase the revenue share, molecular testing companies are focusing more on the development of advanced devices and kits such as WGA kits and complete WGA kits with advanced capabilities.

The global whole genome amplification market is estimated at around US$ 5.08 Bn by the end of 2031, as indicated by a recent report released by Future Market Insights. The global market for whole genome amplification will possibly expand at a CAGR of 7.9% during the forecast period, 2021-2031.

Single Cell WGA Continues to Bring in New ApplicationsIntroduction of massively parallel single-cell genome sequencing is anticipated to offer a new dimension to the understanding of genetic diversities in complex biological systems.

Single cell WGA is a method used to examine the sequence information with the optimized next generation sequencing technologies, only from a single cell. This method is considered to be a powerful tool that helps to understand the ins and outs of genetics by bringing the entire genome structure to a cellular level.

Since this method offers a high-resolution view of the genomic sample, its adoption will continue to be on the rise in diverse biological fields such as microbiology, immunology, neurobiology, cancer research, and tissue mosaicism.

Single cell WGA also plays a crucial role in conveying new applications to the market, eventually pushing the market growth further through 2031.

Request Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-1873

New Technology Assessment in Branded WGA ProductsAs a move towards better results and implementation of advanced technology, novel techniques are being introduced in the new WGA products.

The TruePrime Single Cell WGA Kit (Expedeon Ltd.), utilizes a unique and reliable method to achieve accurate genome amplification from single cells. TruePrime technology uses a revolutionary novel multiple displacement amplification (MDA) method based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 DNA polymerase to amplify uniformly total genomic DNA either a single or a few cells.

Similarly MALBAC Multiple annealing and Looping Based Amplification Cycles) technology and PicoPLEX® WGA kit (Rubicon Genomics), with patented technology are the other options that have been unveiled as the latest and advanced technologies which are more efficient and optimized in the results and analysis outcomes.

Companies Focusing on Better Product Quality through Life Science ResearchIncreasing prevalence of infectious diseases and oncology disorders has increased the demand for WGA devices and kits, fueling the growth of companies dealing in WGA kits.

Despite the market having several large players as well as multiple smaller companies, there are limited companies that have a complete focus on being a provider of life science products and reagents.

Vendors have different specializations and product offerings, with most of the large companies combining research products and reagents with equipment, in-vitro diagnostics tools etc.

However, the companies that have a sole focus on this market can have better growth prospects in the coming future.

They can ensure better quality of products, customer loyalty and an established distribution network that can cater to product availability around the globe.

The key players of the market, including GE Healthcare, Sygnis AG, Illumina, Inc., Merck KGaA, Thermo Fisher Scientific Inc., and Active Motif are inclined more towards strategic acquisitions and mergers.

They are also looking for distribution and collaboration agreements to help improve their product reach. It will also help them serve end users better, with diagnostic consulting and good laboratory practices. High price point may remain a major challenge for companies.

Orthokeratology Market 2022 Outlook, Current and Future Industry Landscape Analysis 2028

Orthokeratology has been considered to facilitate the elimination of contact lens related vision problems, providing patients with the freedom to experience an active lifestyle.

While this factor will continue to play a pivotal role in growing adoption of Ortho-K lenses, Future Market Insights has discovered a few other factors that are likely to impact the growth of orthokeratology market in near future. In a recently released report, titled “Orthokeratology Market: Global Industry Analysis 2013-2021 and Opportunity Assessment, 2022–2028,” the performance of global market for orthokeratology is assessed for a 10-year period 2022-2028.

Increasing online efforts in patient education and awareness about Ortho-K, coupled with an intensifying rate of success of orthokeratology lenses in recent years, is expected to strengthen the prospects for global orthokeratology market, over the next decade. The market is likely to witness a promising CAGR of 7.4%; whereas, the global revenue is anticipated to reach beyond US$ 88 million by the end of 2028.

While increasing prevalence of myopia stands as a key factor impacting the market growth, several advantages of Ortho-K lenses over the conventional contact lenses have been recognized to be pushing adoption of orthokeratology among sports persons. A few restrictions arising in case of LASIK surgery will also be reportedly responsible for growing inclination for Ortho-K. On the flipside, the adoption of orthokeratology lenses among the myopic patient is less than 0.5%, which is a major factor deterring the growth of the market. In few under developing economies, patient are not able afford the high cost of ortho-k lenses and also the high fees of ophthalmologists and optometrists which will also deter the growth of market to some extent.

Orthokeratology Market Historical Analysis (2013-2021) Vs. Market Outlook (2022-2028)The global orthokeratology market value increased at around 6.9% CAGR from 2013 to 2021.

Orthokeratology (Ortho-K), an emerging treatment option for myopia, presbyopia, hyperopia, and astigmatism, is a non-invasive process and works on the principle of corneal replacement. At present, there are two FDA approved Ortho-K therapies: Corneal Refractive Therapy (CRT) and Vision Shaping Treatment (VST).

Patients availing these treatments need to wear the Ortho-K lenses for 6 to 8 hours at night during their sleep, and this reshapes their cornea to facilitate clear vision during the daytime.

Orthokeratology has been considered to facilitate the elimination of contact lens-related vision problems, providing patients with the freedom to experience an active lifestyle. While this factor will continue to play a pivotal role in the growing adoption of Ortho-K lenses.

Increasing online efforts in patient education and awareness about Ortho-K, coupled with an intensifying rate of success of orthokeratology lenses in recent years, is expected to strengthen the prospects for the global orthokeratology market, over the coming years.

While increasing prevalence of myopia stands as a key factor impacting market growth, several advantages of orthokeratology lenses over conventional contact lenses have been recognized to be pushing the adoption of orthokeratology devices among sportspersons.

The orthokeratology market is projected to expand at a CAGR of around 7.3% from 2022 to 2028.

Orthokeratology market

Request Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-3142

Myopia Continues to Remain the Most Influencing Indication, Accounting for a Major Revenue ShareMyopia is expected to remain a key indication driving the demand for orthokeratology, worldwide. With over 70% share of the total market value estimated for 2028, myopia will also provide an extensive scope for innovation opportunities. Hyperopia, followed by astigmatism, will represent the next key indicative factor, which is anticipated to drive market growth over the forecast period.

Demand from Optometry Clinics Accounts for a Share that Equates More than Half of the Market ValueAmong all distribution channels, optometry clinics will reportedly continue to generate the maximum demand for Ortho-K, accounting for a share of more than 50% to the total market value through 2028. Ophthalmic clinics are expected to hold a decent revenue share throughout the assessment period, whereas hospitals are likely to emerge as the most opportunistic distribution channel.

MEA Still Struggles through Low Awareness LevelNorth America and Europe, which represent the key regional markets, will reportedly account for a collective value share of around 60% through 2028. Asia Pacific excluding China and Japan is slated for modest growth, whereas MEA will continue to witness sluggish growth rate owing to relatively lower consumer awareness about availability and use of Ortho-K lenses.

Key Segments Covered in Orthokeratology Industry SurveyOrthokeratology Market by Indication

  • Myopia
  • Presbyopia
  • Hyperopia
  • Astigmatism

Orthokeratology Market by Distribution Channel

  • Hospitals
  • Optometry Clinics
  • Ophthalmology Clinics

Orthokeratology Market by Region

  • North America Orthokeratology Market
  • Latin America Orthokeratology Market
  • Europe Orthokeratology Market
  • East Asia Orthokeratology Market
  • South Asia & Pacific Orthokeratology Market
  • Middle East & Africa (MEA) Orthokeratology Market\

Arthroscopy Procedure and Products Market 2021 Outlook, Current and Future Industry Landscape Analysis 2031

ESOMAR-certified consulting firm Future Market Insights, in its updated report, projects a steady growth of the arthroscopy procedures and products market between 2021 and 2031. The market is expected to reach a valuation of approx. US$ 6488.4 Mn in 2021.

Rising prevalence of knee osteoarthritis among geriatric population and increasing number of knee arthroscopy conducted worldwide have augmented the market growth. Increasing application in sports medicine, and ease in regulatory approval such as the U.S. Food & Drug Administration are the factors driving growth.

Due to the non-invasive nature and benefits of arthroscopy, patients suffering from severe osteoarthritis are preferring knee arthroscopy, which is accelerating the market growth.

Growing incidence of osteoarthritis across the U.S., Germany, the UK, and China have propelled the adoption of knee arthroscopy surgeries in those regions.

With such rising statistics, healthcare professionals and government are increasing the initiatives to provide rehabilitation and facilities to curb the additional cost. Based on such factors, the market is anticipated to witness healthy growth at over 7.7% CAGR during 2021 and 2031.

However, increasing risk of edema and other infections such as blood clots in the joints might restrict the market growth. Also, high cost of surgery and procedures across low economies such as Brazil, India and other countries in Latin America will hamper the market growth.

Key Takeaways from FMI’s Arthroscopy Procedures and Products Market Study

  • In terms of procedure type, knee arthroscopy will account for over 50% of the global market share
  • Arthroscopic implants segment will account for highest share of the arthroscopy procedures & products market during the forecast period
  • The U.S. will emerge as the most lucrative market backed by the rising prevalence of degenerative disease among geriatric population
  • Germany and the U.K., collectively, will emerge as the most lucrative market across Europe in the upcoming decade
  • Japan is anticipated to emerge as a lucrative market backed by the high prevalence of rheumatoid arthritis and osteoarthritis among elderly

 “Increasing prevalence of osteoarthritis and growing degenerative disease among elderly population have encouraged the leading players to engage in research & development activities to develop advanced procedure & instrument for non-invasive surgeries,” says the FMI analyst. 

Request Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-1386

Competitive LandscapeProminent players in the market are focusing on strategic mergers and collaboration to expand their global footprint in the market.

New product launches coupled with increasing research & development activities for the development of advanced arthroscopy instruments & devices will also be one of the key strategy to enhance their customer base for market players.

For instance, couple of years back, leading player, Smith & Nephew entered into a distribution agreement with OrthAlign, a U.S. based private company to develop medical devices and distribute their Total-Knee Arthroplasty (TKA) technology across several countries in Africa and Middle East.

Also, in 2018, Ceterix® Orthopedics, Inc., a leader in the development of cutting-edge surgical tools for orthopedic surgeons announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of NovoStitch® Pro Meniscal Repair System – a size 0 suture cartridge – offering surgeons more options to repair meniscal tears for arthroscopic surgeries.

Arthroscopy Procedure and Product Market by CategoryBy Product Type:

  • Arthroscopes and Visualization Systems
  • Arthroscopic Resection Systems
  • Arthroscopic Fluid Management Systems
  • Arthroscopic Implants
    • Knee Implants
    • Shoulder Implants
    • Hip Implants
    • Other Implants
  • Arthroscopy Radiofrequency (RF) Systems
  • Arthroscopic Drills and Fixation Systems
  • Other Arthroscopy Instruments and Accessories

By Procedure Type:

  • Shoulder Arthroscopy
  • Hip Arthroscopy
  • Knee Arthroscopy
  • Elbow Arthroscopy
  • Small Joints Arthroscopy
  • Others

By Region:

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • Asia Pacific excluding Japan
  • Japan
  • Middle East and Africa (MEA)

Europe Viscosupplementation Market 2016 Outlook, Current and Future Industry Landscape Analysis 2026

Future Market Insights (FMI) delivers key insights on the Europe viscosupplementation market in its upcoming report titled, “Viscosupplementation Market: Europe Industry Analysis and Opportunity Assessment, 2016-2026”. In terms of revenue, the Europe viscosupplementation market is projected to register a healthy CAGR of 5.1% during 2016-2026.

FMI’s report has segmented the market on the basis of product type, end user and region.

Based on product type, the market has been segmented into one injection viscosupplementation, three injection viscosupplementation and five injection viscosupplementation.

Single injection viscosupplementation product type segment is expected to emerge as the most popular segment over the forecast period, driven by better patient compliance as the treatment reduces the need for multiple hospital visits. The segment is expected to register the highest CAGR of 6.7% during the forecast period.

Five injection viscosupplementation product type segment is expected to witness a decline in market share in terms of revenue from 29.0% in 2015 to 23.3% in 2026. This decline is attributed to more incidence of side effects and repeated patient visit requirements associated with five injection viscosupplementation. Reimbursement cutbacks and high injection costs are other factors that can curtail demand for five injection viscosupplementation.

By end-users, the market is segmented into hospitals, ambulatory surgical centres and orthopaedic clinics. Hospitals end-use segment is expected to witness significant demand for viscosupplementation, registering a CAGR of 4.3% over the forecast period. Better reimbursement options and increasing patient preference for single injection cycle for osteoarthritis treatment is expected to drive demand for one injection viscosupplementation in the orthopaedic clinics segment over the forecast period.

Browse the full “Viscosupplementation Market: Europe Industry Analysis and Opportunity Assessment, 2016 – 2026” market research report at https://www.futuremarketinsights.com/reports/europe-viscosupplementation-market

Europe Viscosupplementation Market Trends

Key trends in the viscosupplementation market are the use of single injection cycle for osteoarthritis treatment and introduction of new combination products in the market. For example, the product pipeline of major players in the viscosupplementation market involves combining corticosteroid injections, which help in relieving pain associated with osteoarthritis, with long-lasting effects of hyaluronic acid, which lasts for nearly six months. Further, regional competition within EU countries, especially in five injection cycle, is leading to entry of new market players. Europe is a mature market in terms of generic products and it is therefore relatively easier to obtain CE mark in Europe than it is to obtain the U.S. FDA approval.

Western Europe has been estimated to dominate the Europe viscosupplementation market in 2015, attributed to factors such as the presence of key regional players, strong distribution network and better healthcare infrastructure in the region.

Request Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-eu-1383

Key Players in Europe Viscosupplementation Market

Some key players in the Europe viscosupplementation market are Anika Therapeutics Inc., Sanofi S.A., Zimmer Biomet Holdings, Meda AB, Ferring B.V, Fidia Pharmaceutici S.p.A,   and Bioventus LLC. We have discussed individual strategies followed by these companies in terms of enhancing product designs, creating new manufacturing facilities, market consolidation and advanced R&D initiatives. The report concludes with key takeaways that could help players already present in the market and new players planning to enter the market in the long run.

Key Segments

  • Product Type
    • Single Injection Viscosupplementation
    • Three Injection Viscosupplementation
    • Five Injection Viscosupplementation
  • End User
    • Hospitals
    • Ambulatory Surgical Centres
    • Orthopaedic Clinics

 Key Regions/Countries

  • Western Europe
    • U.K.
    • France
    • Germany
    • Spain
    • Italy
    • Nordics
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Rest of Eastern Europe

Companion Animal Specialty Drugs Market 2021 Outlook, Current and Future Industry Landscape Analysis 2031

Future Market Insights, Dubai: As per ESOMAR-certified consulting firm Future Market Insights (FMI), the global companion animal specialty drugs market registered steady year-on-year (YoY) growth at 5.42% CAGR in 2021.

Increasing pet adoption is a major factor, fuelling the demand for animal nutrition and behavioral products, thereby accelerating sales. With increasing rate of obesity among the pet, demand for anti-obesity drugs have burgeoned over the past few years.

Adoption of canine and feline pets increased during the FQ-20, due to the outbreak of COVID-19 and consequent global shutdown. Adoption of dogs is quite high, especially among the geriatric population. This is expected to drive the demand for antibiotics, skin-care, and nutritional products for pets.

As per FMI, the market is expected to reach a valuation of US$ 36,104.66 Mn in 2021 owing to the increasing demand for anti-obesity drugs across veterinary clinics. Alongside this, prevalence of canine vector-borne diseases due to bacteria and protozoa infection will fuel the demand for parasiticides in the next decade.

Key Takeaways from FMI’s Companion Animal Specialty Drugs Market Study

  • By product type, parasiticides will dominate the market, accounting for over 32% of global market share.
  • In terms of distribution channel, veterinary clinics are expected to lead the segment contributing over 52% of value share by 2031
  • In terms of technology type, drying technology is predicted to exceed US$ 89 Bn by end 2031
  • The U.S. will emerge as the leading market across North America backed by the high adoption of pet dogs
  • Germany and the U.K. are anticipated to lead the Europe’s Companion animal specialty drugs market, owing to the growing obesity rate in dogs
  • Increasing cases of neglect and animal cruelty in India will bolster the demand for companion animal specialty drugs through 2021

“The demand for compounded medications and anti-obesity drugs for animals will continue increasing in the coming years. This has encouraged some of the leading companies to focus on research initiatives to launch novel drugs to facilitate improved care for companion animals. This will create impressive growth opportunities in the coming years,” says the FMI analyst. 

Competitive LandscapeZoetis Inc., Merck and Co., Inc., Bayer AG, Eli Lily and Co. and Boehringer Ingelheim GmbH are the key players operating in the companion animal specialty drugs market. among others are some prominent players operating in the Companion animal specialty drugs market.

For instance, in July 2020, Boehringer Ingelheim announced the launch of two new products, NexGard and Broadline, to provide comprehensive parasite treatment for dogs and cats, to expand their product portfolio for the India market.

As per the report, key players are focusing on product introduction and launches to expand their product portfolios. Key player are also involved extensively in strategic acquisition activities which has led to severe competition among companion animal specialty drugs market players.

For example, on August 4,2021, Zoetis, the Parsippany-based animal health company announced the acquisition of a leading Australian-based Jurox’s veterinary medicines, maker of livestock and companion animal medicines.

Request Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-3984

What else is in the report?Future market insights offers a unique perspective and actionable insights on companion animal specialty drugs market in its latest study, presenting historical demand assessment from 2016 – 2020 and projections from 2021-2031 based on product type (antibiotics, anti-inflammatory drugs, parasiticides, heartworm, behavioral products, nutritional products, anti-obesity drugs, skin care products and vaccines), distribution channel (veterinary hospitals, veterinary clinics and pharmacies and drug stores) in seven key regions (North America, Latin America, Eastern Europe, Asia Pacific excluding Japan, Western Europe, Japan and Middle East & Africa)

Companion Animal Specialty Drugs Market by CategoryBy Product:

  • Antibiotics
  • Anti-Inflammatory Drugs
  • Parasiticides
  • Heartworm
  • Behavioral Products
  • Nutritional Products
  • Anti-Obesity Drugs
  • Skin Care Products
  • Vaccines

By Distribution Channel:

  • Modern Trade
  • Online Distribution
  • Neighborhood Stores
  • Other Retail Format

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa (MEA)

Cell Line Development Market 2022 Outlook, Current and Future Industry Landscape Analysis 2028

According to International Agency for Research on Cancer, the number of new cancer cases per year is expected to rise to 23.6 million by 2030 globally. In recent times, cell line development and its applications are considered as potential tools in oncology research. Cell lines are projected to be used for development of new treatment pathway for various disease including cancer and neurological diseases.

Sales Analysis of Cell line Development from 2013 to 2021 Vs Market Outlook for 2022 to 2028

The market value for cell line development holds nearly 11.7% of the overall US$ 37.3 Mn drug discovery market in 2021.

Compared to the existing mammalian expression systems, the human cell lines possess the ability to produce proteins analogous to naturally synthesized proteins in the human body. This property is advantageous for the advancement in protein therapeutics, and acts as a heavy driver towards the growth of the biopharmaceutical industry. The growth of these industries pulls up the demand of cell line development market. The advantage of using human cell lines for protein production is factored in through the prospects of the resultant recombinant protein to bear post-translational modifications which are consistent with the endogenous human proteins.

Increasing burden of disease had propelled the development of new treatment pathways for diseases such as cancer and neurological disorders. The applications of hybridoma cell lines and recombinant cell lines in the development of therapeutic proteins has led to the growth in demand of cell line development market. The human cell lines, specifically the stem cell lines hold a potential stance for the treatment of various degenerative diseases, and hence paves way to novel drug therapy in regenerative medicine.

Moreover, the increasing development and production of biosimilars, owing to the patent expiry of branded therapeutics has positively impacted the growth of the cell line development market. The global scale development of bio therapeutics with cell line development has further fostered the development of a number of protein based therapeutics, assisting the growth of high-expression cell lines. These factors promote the expansion of the cell line development market on a global scale.

The global cell line development market expanded at 6.1% CAGR over the past 8 years from 2013 to 2021. The market is expected to expand at a considerable growth rate over the next six years (2022-2028) at a CAGR of close to 7.5%

cell line development market

Request Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-7566

According to a latest research by Future Market Insights (FMI), the global cell line development market size is anticipated to account for over US$ 7,200 Mn, in terms of value, by 2028 end. The report on cell line development market further projects significant growth potential with CAGR at 7.2% through 2028.

Rapid increase in prevalence of cancer and neurology disorders and lack of efficient treatment solution for these diseases has created the need of more advanced and efficient treatment pathway. Companies and government organizations are investing on research and development activities and are also focusing more on cell line development in search of new cellular pathway to develop novel drugs. The increased spending on biosimilar R&D from exiting biopharmaceutical companies would provide boost to cell line development market.

In recent time the contract research organizations are focusing on cell line development and cell line research activities. According to National Institutes of Health (NIH) the estimated total federal spending on all type of stem cell line research for 2017 is US$ 1.58 Bn. In developing countries like India, government is supporting cell line development through national funding agencies like Department of Biotechnology (DBT), Indian Council of Medical Research (ICMR), and Department of Science and Technology (DST).

Regenerative medicines are the next generation treatment solution and Cell Line Development or Cell Culture is a vital part for regenerative medicine. Increasing demand of regenerative medicines in cancer treatment would positively impacting the growth of Cell Line Development market over the forecast period.

The biopharmaceutical companies operating in development of novel drug line are expected to hold promising revenue opportunity in cell line development market.

Future Market Insights (FMI) has segmented the cell line development market based on product type, cell line source type, end user, type of cell line and region.

Product type segment in cell line development market is segmented into media and reagents, equipment and accessories. Reagents and Media are required from incubation to preservation of cell lines. These products are expensive and have repetitive use in cell culture or bio-production. Reagent and media segment in cell line development market is expected witness noteworthy growth in terms of revenue owing to rapid increase in demand in cell culture and cell based assays.

Cell line development market by cell line source is categorized into mammalian cells and non-mammalian cells. Mammalian cell line development is anticipate to witness significant growth in overall cell line development market. This growth of mammalian cells segment in cell line development market is driven by increased production of biologics drugs which require mammalian cells. Increasing antibody production is the major driving factor behind the growth of mammalian cell lines segment in cell line development market.

Mammalian cell lines are used to create therapeutic proteins through genetic building and antibodies through viral infection. For example, Gaucher’s disease, which is a genetic disorder characterized by lack of β-glucocerebrosidase enzyme and can be treated by Cerezyme which is a recombinant enzyme produces in mammalian cell lines. Mammalian cell lines are also useful in production of antibodies and other therapeutic agents such as specific binding proteins that can neutralize disease causing agents in the body. For example Under cell line type segment in cell line development market, recombinant cell line development are the most demanding type of cell line due to large application in biologics production, protein interaction, gene activation, toxicity testing and drug screening.

Growing application recombinant cell line development in drug toxicity testing is expected to boost the growth of overall cell line development during the forecast period

North America and Europe cell line development market will dominate in owing to increasing government funding in cell line development research and rising spending on biosimilar developments. Asia Pacific cell line development market is expected to grow at a high growth rate due to increased number of research organization engaged in novel biologics and biosimilar fastest revenue growth in overall cell line development market.

The Asia Pacific region in Cell line development market is anticipate to witness increasing demand of biopharmaceuticals and regenerative medicines are expected to boost the growth of the cell line development market.

FMI’s report tracks some of the key companies operating in the cell line development market, such as Selexis SA, GE Healthcare, Corning Incorporated, Thermo Fischer Scientific, Inc., American Type Culture Collection (ATCC), Lonza (Sartorius Stedim Biotech S.A.), Danaher Corporation, Merck KGaA, WuXi Biologics.

Key Market Segments Covered in Cell line development Market ResearchBy Product Type:

  • Reagent and Media
  • Equipment
  • Accessories and consumables

By Source Type:

  • Mammalian cell line
  • Non-mammalian cell line

By End User:

  • Biopharmaceutical Companies
  • Contract Research Organizations
  • Academics and Research Institutes
  • Biotechnology Companies

By Cell Lines:

  • Recombinant cell lines
  • Hybridomas
  • Continuous cell lines
  • Primary cell lines

By Region:

  • North America
  • Latin America
  • Europe
  • CIS & Russia
  • Japan
  • APEJ
  • MEA

Lacrimal Devices Market 2020 Outlook, Current and Future Industry Landscape Analysis 2029

Introduction of upgraded and highly precise lacrimal duct stent tube for canalicular stenosis or obstruction and congenital nasolacrimal duct obstruction remains a key booster to the growth of lacrimal duct stent tube market. The global market for lacrimal duct stent tube is projected for a promising 6% CAGR during 2019 – 2029, as suggested by a new Future Market Insights (FMI) report.

There has been higher preference for bicanalicular lacrimal duct stent tube over its monocanalicular counterpart, attributing to the former’s high success rate, suitability for stenting in older patients, and better clinical outcomes. Moreover, increasing prevalence of retina-related conditions, primarily imperforation of nasolacrimal duct, epiphora both in infants and adults, and conditions necessitating dacryocystorhinostomy are other factors responsible for propelling revenue growth of the lacrimal duct stent tube market.

Key Takeaways – Lacrimal Duct Stent Tube Market Study

  • Bicanalicular lacrimal duct stent tube is expected to contribute three fourth of revenue share in the lacrimal duct stent tube market owing to its high success rate in stent placement.
  • Hospitals captured maximum share of the lacrimal duct stent tube market owing to highest patient footfall followed by ophthalmic clinics.
  • Attributed to growing patient pool for retinal diseases, especially due to premature births, contributed to the dominance of North America in the lacrimal duct stent tube market.
  • Increasing awareness for availability of the treatment for nasolacrimal duct stent obstruction among caregivers of prematurely born babies and increasing number of skilled professionals are expected to drive growth of the lacrimal duct stent tube market in East Asia.
lacrimal duct stent tube market share by region

Manufacturers Emphasizing Advanced Product Development

Numerous organizations are focusing on new product development for lacrimal duct stent tube. In June 2019, FCI Ophthalmic offered a complete line of BIKA stents namely, BIKA, BIKA for DCR, and Infant BIKA covering a range of sizes that will benefit most of the congenital nasolacrimal duct obstruction (CNLDO) and dacryocystorhinostomy (DCR) cases.

Request Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-9649

Know More About Lacrimal Duct Stent Tube Market Report

Future Market Insights brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each segment from 2014 to 2029. The global lacrimal duct stent tube market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on lacrimal duct stent tube market on basis of product type (monocanalicular lacrimal duct stent tube, bicanalicular lacrimal duct stent tube), and end user (hospitals, ophthalmic clinics, ambulatory surgical centers), across seven major regions.

LACRIMAL DUCT STENT TUBE MARKET TAXONOMYThe global lacrimal duct stent tube is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Product

  • Monocanalicular Lacrimal Duct Stent Tube
  •  Bicanalicular Lacrimal Duct Stent Tube

End User

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

Region

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Asia (MEA)

Urinary Tract Infection Testing Market 2019 Outlook, Current and Future Industry Landscape Analysis 2029

Urinary Tract Infection Testing: Market Insights

Urinary tract infection is one of the most common bacterial infection affecting almost 150 million people worldwide. Urinary tract infection mostly occurs in urinary tract which is caused by bacteria, viruses and fungi. Some of the bacteria that cause urinary tract infection such as Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, Proteus species and Enterococcus species. According to Center for Disease Control and Prevention urinary tract infection surveillance report 2018, an estimate of 93,300 morbidity cases were observed in acute care hospitals. Recurrent urinary tract infection is a major health issue in females across the globe. According to European Association of Urology, there is an increase in bacterial resistance to antibiotics in the region which leads to more research and development for novel therapeutics. With latest upcoming techniques, urinary tract infection testing market will fuel the growth of the market

Urinary Tract Infection Testing: Market Dynamics

Urinary tract infection is expected to register significant growth in the market owing to rising prevalence of urinary tract infection globally. Increasing geriatric population is a another factor that is expected to boost the demand for urinary tract infection testing as the elderly population is at the high risk of contracting the same. Moreover, patients that use urinary catheters are more likely to contract complicated urinary tract infection. This adds on another factor that will spur the growth of the urinary tract infection testing market. Apart from this, manufacturers are currently focus on developing new imaging techniques for urinary tract infection testing which may drive the growth of the urinary tract infection testing market. However, stringent and complex regulatory approvals for new launch of equipment and lack of government funding for research and development in developing countries may restrain the growth of the market.

Urinary Tract Infection Testing Market: Overview

There has been an increase in the number of urinary tract infection patients across the globe. Urinary tract infection contributes to the second-largest patient pool in the world. Increasing prevalence and demand for better treatment option is likely to foster the growth of the market. Launch of new testing kits and devices will accelerate the growth of the urinary infection testing market. For instance, in June 2019, MiDOG, LLC announced the launch of new collection of urine kit and test for the diagnosis of fungal and bacterial pathogens in urinary tract infections of canine. With the launch of new technologies and increase in number of urinary tract infection testing kits and devices players, the urinary tract infection testing will spur the growth of the market.

Request Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-10134

Urinary Tract Infection Testing: Region-wise Outlook

On the basis of geography, the global urinary tract infection testing market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, and Asia Pacific excluding Japan and Middle East & Africa. North America is expected to anticipate substantial revenue generation in urinary tract infection testing market owing to advancement in research and development, increased in launch of new urinary tract infection testing devices and instruments. Europe also share significant revenue generation in urinary tract infection testing market owing to increase in adoption of new technologies and improved healthcare infrastructure. Asia Pacific has significant potential in stimulating the growth of the urinary tract infection testing market due to increasing prevalence of urinary tract infection and rising awareness about various bacterial infection. Middle East and Africa has less impact in urinary tract infection testing market due to poor healthcare infrastructure and less availability of diagnostic procedures which may hinder the growth of the urinary tract infection testing market.

Urinary Tract Infection Testing Market: Key Players

Some of the key players present across the value chain of the global urinary tract infection testing market are Laboratory Corporation of America Holdings, Stryker, PENTAX Medical, Seimens Healthineers, Sysmex Corporation, Cardinal Health, Roche Diagnostics, Arkray Inc, Alere Inc., Streck, Quidel Corporation, Beckman Coulter, Bio-Rad Laboratories, DIRUI, ACON Laboratories, URIT Medical Electronic Ltd.

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Value Chain

The regional analysis includes:

  • North America (U.S., Canada)
  • Latin America (Mexico. Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
  • Eastern Europe (Poland, Russia)
  • Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • The Middle East and Africa (GCC, S. Africa, N. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Urinary Tract Infection Testing Market: Segmentation

The global urinary tract infection testing market is segmented by test types and end user

Urinary Tract Infection Segmentation by Test

  • Laboratory Test
  • Urinalysis urinary tract infection testing
  • Urine culture urinary tract infection testing
  • Susceptibility urinary tract infection testing
  • Non-laboratory Test
  • Kidney and bladder ultrasound urinary tract infection testing
  • Nuclear scans urinary tract infection testing
  • Cystoscopy urinary tract infection testing
  • Voiding cystourethrogram (VCUG) urinary tract infection testing

Urinary Tract Infection Segmentation by End User

  • Hospitals
  • Diagnostics Laboratories
  • Research Institutes
  • Others

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance

At-Home Vaginal pH Test Kit Market 2018 Outlook, Current and Future Industry Landscape Analysis 2028

At-Home Vaginal pH Test Kit Market OverviewAt-Home Vaginal pH Test kits are used to measure the pH of the vaginal secretion. At-Home Vaginal pH Test is a qualitative test to find out the unbalanced pH level of the vaginal secretion. At-Home Vaginal pH Test is performed in case of unusual vaginal symptoms such as unpleasant odor, burning, itching or unusual discharge.At-Home Vaginal pH Test is useful to decide whether the patient suffering from unusual vaginal symptoms. However, the at-home vaginal pH test will not help for the diagnosis of group B streptococcus HIV, gonorrhea, herpes, syphilis, or chlamydia.

At-Home Vaginal pH Test Kit: Drivers and Restraints

At-Home Vaginal pH Test allows the early detection of vaginal infections. A normal vaginal pH is between 3.8 and 4.5. If the vaginal pH is detected using at-home vaginal pH test kits is 5.0 or more indicates the presence of either trichomoniasis or bacterial vaginosis. On the other hand, the lower pH than 3.5 indicates the presence of yeast infection. Moreover, the at-home vaginal pH test kits are a cost-effective option for the early detection of vaginitis at home without visiting the physician. Moreover, the at-home vaginal pH test kit is also useful to maintain the pH balance of vaginal area, early diagnosis of the disorder related to vaginal flora, to prevent the vaginal infection, the at-home vaginal pH test kit is also useful for greater safety during pregnancy, to monitor the effectiveness of any treatment. These factors and advantages are expected to propel the market of at-home vaginal pH test kits.

However, the results of at-home vaginal pH test kits may not be accurate if the woman has recently had intercourse or if the women are on her period. In most of the cases, the patient should still see a physician or gynecologists to get the most correct diagnosis even after using at-home vaginal pH test. These factors are expected to negatively impact the growth of the at-home vaginal pH test kits market.

At-Home Vaginal pH Test Kit Market: Overview

Global At-Home Vaginal pH Test Kit Market has witnessed growth due to rising awareness feminine hygiene and rising incidence of vaginitis.

At-Home Vaginal pH Test Kit Market: Region-wise Outlook

Geography wise, At-Home Vaginal pH Test Kit Market is divided into eight regions such as North-America, Asia- Pacific excluding China & Japan, China, Japan, Western Europe, Eastern Europe, Latin America and Middle-East & Africa. North America’s At-Home Vaginal pH Test Kit Market is expanding because of high adoption rate and it will remain dominant over the period of forecast due to rising incidence of vaginitis and rising awareness for feminine hygiene.

Request Complete TOC Of this Report @ https://www.futuremarketinsights.com/toc/rep-gb-8318

At-Home Vaginal pH Test Kit Market: Key Market Participants

Some of the market participants in the Global At-Home Vaginal pH Test kit market identified across the value chain include: Hometest, Bayer AG, Prestige Consumer Healthcare, Inc., GRÜNSPECHT Naturprodukte GmbH, Vagisil, Dream Future Innovation.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

At-Home Vaginal pH Test Kit Market: Segmentation

To gain a comprehensive and better understanding of the future market equity, the market report is segmented based on the distribution channel and region.

On the basis of distribution channel, At-Home Vaginal pH Test Kit Market can be segmented as:

  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy
  • Fertilization Centers

On the basis of geography, At-Home Vaginal pH Test Kit Market can be segmented as:

  • North- America
  • Eastern Europe
  • Western Europe
  • Asia-Pacific excluding China & Japan
  • China
  • Japan
  • Middle East and Africa
  • Latin America

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current, and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint